Log In
BCIQ
Print this Print this
 

Flivas (Naftopidil)

  Manage Alerts
Collapse Summary General Information
Company Asahi Kasei Pharma Corp.
DescriptionAlpha 1 blocker
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationBenign prostatic hyperplasia (BPH)
Indication DetailsTreat benign prostatic hyperplasia (BPH)
Regulatory Designation
PartnerDong-A Socio Holdings Co. Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/06/2009

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today